© 2021 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Drs Arlene O. Siefker-Radtke and Scott T. Tagawa comment on opportunities for treating metastatic urothelial cancer with FGFR targeted therapies based on current trends in molecular testing and emerging therapies.
November 10th 2021
A discussion on current prognostic and predictive testing assays used to detect FGFR mutations in patients with metastatic urothelial cancer (mUC).
November 17th 2021
The impact of the COVID-19 pandemic on rates of molecular testing used by community oncologists who care for patients with urothelial cancer.
A discussion on molecular testing in the community and recommendations that can address barriers.
November 24th 2021
An overview of the types of health care professionals who may help manage patients with metastatic urothelial cancer throughout their disease course.
The significance of using broad genomic profiling tests to help detect promising biomarkers in metastatic urothelial cancer.
December 1st 2021
Drs Arlene O. Siefker-Radtke and Scott T. Tagawa explain how they would establish goals of therapy and a treatment algorithm for a patient who presents with metastatic urothelial cancer.
Factors that impact the selection of immunotherapy vs chemotherapy for frontline metastatic urothelial cancer.
December 6th 2021
Current recommendations for repeat testing in patients with relapsed metastatic urothelial cancer.
Strategies that can be used to counsel patients on molecular testing for FGFR mutations and what to expect from treatment with erdafitinib.